Beta-lactam antibiotic

Beta-lactam antibiotics are drugs that inhibit bacterial cell-wall synthesis by binding penicillin-binding proteins. Their shared four-membered beta-lactam ring is essential to this activity.

Penicillin-binding proteins: Enzymes that build and remodel bacterial cell walls, including enzymes that cross-link peptidoglycan. Beta-lactams bind these enzymes and block their cell-wall cross-linking activity.
Penicillin: A family of beta-lactam antibiotics characterized by a fused beta-lactam and thiazolidine ring system. Penicillins are the foundational and widely used branch of the class.
Antibiotic spectrum: The range of bacterial species against which an antimicrobial drug is active. Different beta-lactam families cover different bacteria, shaping empiric treatment choices.
Beta-lactamase: A bacterial enzyme that hydrolyzes the beta-lactam ring of susceptible antibiotics. These enzymes directly undermine the chemical feature the drug class depends on.
Alexander Fleming: A Scottish bacteriologist who discovered penicillin’s antibacterial effect in 1928. His observation launched the development of the first widely used beta-lactam antibiotic.
Peptidoglycan: A mesh-like polymer of sugars and peptides that gives most bacterial cell walls strength and shape. The target structure weakens when beta-lactams inhibit its cross-linking.
Cephalosporin: A family of beta-lactam antibiotics built around a beta-lactam ring fused to a dihydrothiazine ring. Cephalosporins are a major branch with generations differing in spectrum and stability.
Antimicrobial susceptibility testing: Laboratory methods that determine whether microorganisms are inhibited by particular antimicrobial drugs. Testing helps identify which beta-lactams can treat an isolate.
Methicillin resistance: Resistance to methicillin and related beta-lactams, commonly caused by altered penicillin-binding protein PBP2a in Staphylococcus aureus. Altered targets can prevent beta-lactams from binding even when their rings remain intact.
Howard Florey: An Australian pharmacologist who led the Oxford team that developed penicillin for clinical use. His team transformed penicillin from a laboratory observation into a therapeutic drug.

Linked from 35 pages